Largest Ever Exhibition of Vermeer Paintings to Open in Amsterdam

A journalist takes images of Girl with a Pearl Earring during a press preview of the Vermeer exhibit at Amsterdam's Rijksmuseum, Monday, Feb. 6, 2023, which unveils its blockbuster exhibition of 28 paintings by 17th-century Dutch master Johannes Vermeer drawn from galleries around the world. (AP)
A journalist takes images of Girl with a Pearl Earring during a press preview of the Vermeer exhibit at Amsterdam's Rijksmuseum, Monday, Feb. 6, 2023, which unveils its blockbuster exhibition of 28 paintings by 17th-century Dutch master Johannes Vermeer drawn from galleries around the world. (AP)
TT

Largest Ever Exhibition of Vermeer Paintings to Open in Amsterdam

A journalist takes images of Girl with a Pearl Earring during a press preview of the Vermeer exhibit at Amsterdam's Rijksmuseum, Monday, Feb. 6, 2023, which unveils its blockbuster exhibition of 28 paintings by 17th-century Dutch master Johannes Vermeer drawn from galleries around the world. (AP)
A journalist takes images of Girl with a Pearl Earring during a press preview of the Vermeer exhibit at Amsterdam's Rijksmuseum, Monday, Feb. 6, 2023, which unveils its blockbuster exhibition of 28 paintings by 17th-century Dutch master Johannes Vermeer drawn from galleries around the world. (AP)

Twenty-eight paintings by Johannes Vermeer go on display at the Rijksmuseum in Amsterdam this week, the largest ever exhibition of works of the 17th-century Dutch master, known for his expertise at rendering light and intimate household scenes.

The show gathers half the works that Vermeer, who died aged 43 and worked slowly, is thought ever to have painted and three-quarters of those that still exist. He likely never saw so many of his own works together at one time.

Rijksmuseum director Taco Dibbits said Vermeer was a man who lived with a large family and had a busy life as an art dealer, but still managed to obsessively refine works of quiet beauty, bathed in light rendered with almost photographic accuracy.

"It's this ... complete focus and tranquility in his paintings that we still love today," Dibbits said.

Alongside famed works like "Girl With A Pearl Earring" (1664) and "The Milkmaid" (1659), the exhibit features Vermeer's two known outdoor paintings, several large canvases, and a string of his portrayals of women -- including playing instruments, reading and working.

"What's quite striking when you look at Vermeer is that in his paintings, it's mostly women who are the protagonists," said curator Pieter Roelofs, noting Vermeer had seven daughters.

Though no letter written by Vermeer exists, a key document is an inventory of possessions drawn up after his death, which left the family in debt. Furniture and many objects mentioned on the list appear in the paintings.

Roelofs said major advances have been made in understanding how Vermeer worked, including identifying pinholes at the focal point in some paintings such as "The Milkmaid", part of a system of strings he used to help ensure perfect perspective.

Artists and scholars dispute whether Vermeer may have made use of a "camera obscura", a forerunner of the modern photocamera.

Roelofs said Vermeer's works are more than something a good eye and skilled hand can create. Recent analysis shows the composition of "The Milkmaid" changed several times, notably by stripping things out to simplify it.

"That is what Vermeer is: it's never good enough and he keeps working on it until he thinks its sufficient to hand over to clients," Roelofs said.

Author Tracy Chevalier, whose novel "Girl with a Pearl Earring" was adapted to a movie of the same name, said for her the exhibition evoked an image of Vermeer as a reserved man who "plays his cards close to his chest."

"His paintings are so quiet and there are no children ... he must have compartmentalized his life and said 'no, no kids in the studio'."

Museums in Germany, France, Japan, Britain, Ireland and the United States contributed to the exhibition, which opens on Friday and runs until June.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”